FILING ANALYSIS · TUESDAY, NOVEMBER 10
Upstream Bio, Inc. UPB — 8-K: Results of Operations and Financial Condition
neutral
Upstream Bio reported a net loss of $41.2 million for the quarter ended September 30, 2026, and had cash, cash equivalents and short-term investments of $207.4 million, which is expected to fund planned operations through 2027. The company plans to initiate Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027, but there are no quantified surprises in the announcement.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →